has provided a positive opinion for Advanced Therapy Medicinal Product (ATMP) classification for the company's gene therapy candidate OCU400 to treat Retinitis pigmentosa. A phase 3 study of ...

Ocugen, Inc. has announced that the European Commission has given a positive opinion for the classification of its gene therapy product, OCU400, as an Advanced Therapy Medicinal Product (ATMP) by ...

Ocugen (NASDAQ:OCGN) said it has received a positive opinion from European Medicines Agency regulators for Advanced Therapy Medicinal Product classification for its gene therapy OCU400 in the ...

Committee for Advanced Therapies for OCU400 Advanced Therapy Medicinal Product classification. OCU400 is the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa indication.

The Cell and Gene Therapy Catapult (CGT Catapult) presented the data in its UK 2024 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database. The UK maintained its position as a highly ...

Despite its significant potential, Europe trails North America and the Asian Pacific in Advanced Therapy Medicinal Product (ATMP) development, clinical trials, and investment. Belgium however ...

Belgian university hospitals UZ Leuven and KU Leuven are investing €14 million in a new facility for the production of Advanced Therapy Medicinal Products (ATMPs). It’s expected to be ...